Loading
companiesCompany
Geron Corporation
Geron is the Californian company behind imetelstat, the first telomerase inhibitor to reach approval, cleared by the FDA in 2024 for lower-risk myelodysplastic syndromes with transfusion-dependent anaemia.
Also called: Geron
Overview
Geron Corporation, based in Foster City, California, spent three decades on telomerase biology before its oligonucleotide telomerase inhibitor imetelstat (Rytelo) was approved by the FDA in June 2024 for adults with lower-risk myelodysplastic syndromes and transfusion-dependent anaemia who had failed or were ineligible for erythropoiesis-stimulating agents, on the IMerge trial. Imetelstat is also in a phase 3 trial in relapsed or refractory myelofibrosis. Company facts are from the official website and FDA approval records.
Headquarters
Foster City, CA, US
Scorecard
All companies#249of 1244 companies, score 20
- approved products +6
- modalities +2
- regions +2
- registry trials +10
1 approved, 0 in phase 3, 0 earlier, 0 targets, 24 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
ApprovedTelomerase inhibitor (oligonucleotide)
Imetelstat · Rytelo
Imetelstat is a lipid-linked oligonucleotide that binds the RNA template of telomerase, the enzyme cancer cells use to stay immortal, and it is the first telomerase inhibitor approved for any cancer. In lower-risk myelodysplastic syndromes it freed 40% of transfusion-dependent patients from transfusions for at least eight weeks versus 15% on placebo, once growth factors have failed.
Similar pages
- Companymedac
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag fda-oce-applicant.
- CompanyGamida Cell
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag fda-oce-applicant.
- PersonUwe Platzbecker
- TechnologyOligonucleotide therapeutics
Shares IMerge, IMpactMF, Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy, Imetelstat.
- TargetCDA
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis).
- TargetSLX4
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis).
- TargetDDX41
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis).
- TrialA Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis).